KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $79.6 million.

  • Royalty Pharma's Interest Expenses rose 1963.43% to $79.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.3 million, marking a year-over-year increase of 3490.14%. This contributed to the annual value of $225.5 million for FY2024, which is 2047.42% up from last year.
  • Royalty Pharma's Interest Expenses amounted to $79.6 million in Q3 2025, which was up 1963.43% from $68.7 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Interest Expenses ranged from a high of $79.6 million in Q3 2025 and a low of $37.4 million during Q1 2021
  • Its 5-year average for Interest Expenses is $51.6 million, with a median of $47.0 million in 2021.
  • Per our database at Business Quant, Royalty Pharma's Interest Expenses tumbled by 3017.51% in 2021 and then surged by 4754.25% in 2025.
  • Royalty Pharma's Interest Expenses (Quarter) stood at $47.0 million in 2021, then fell by 0.04% to $47.0 million in 2022, then rose by 0.64% to $47.3 million in 2023, then surged by 39.16% to $65.8 million in 2024, then grew by 20.99% to $79.6 million in 2025.
  • Its Interest Expenses was $79.6 million in Q3 2025, compared to $68.7 million in Q2 2025 and $65.3 million in Q1 2025.